Most Read

Under the agreement, the two companies will use e-therapeutics’ network-driven drug discovery platform for the identification of new therapeutics approaches to treat Type 2 diabetes, which currently accounts

The announcement is the latest in a series of strategic investments at PCI, demonstrating its market-leading presence in Biotech therapies, supporting medicines destined reach to more than 100

Jointly developed with Microsoft and powered by Azure, Adents Prodigi allows for secure data exchange and helps leverage the power of serialisation data to improve business practices. Cristers

The candidate, known as E2814, is an anti-tau monoclonal antibody set to be tested in human trials for the first time to assess its ability to slow the

The recalled lots of the product have been found to potentially have higher concentrations of ibuprofen. There is a remote possibility that infants, who may be more susceptible

Phase III studies PEARL1 and PEARL 2 are planned to include more than 2,000 CSU patients. Charité-Universitätsmedizin Allergie-Centrum-Charité Department of Dermatology and Allergy Dermatology and Allergy Professor and

Momenta had previously guided that it planned to file a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the fourth quarter of this

The companies have entered into a collaboration and license agreement for TR009 (formerly known as ABL001 or NOV1501), an ABL developed bispecific antibody candidate targeting two important angiogenic

GSK’s consumer healthcare portfolio has long been regarded as high quality, safe and effective, maintaining a quality image and loyal base of consumers. OTC medications allow practitioners and